Ciloa says its exosomes can ‘deliver’ large molecules and viral proteins to specific organs and is setting up a clinical plant in Montpellier, France. The €1 million ($1.2 million) investment will be used to create an exosome production unit at Ciloa’s site in Montpellier. The facility will be a technological demonstrator that will be the prototype for larger projects of production of customized exosomes, capable of producing around 1,000 doses to support early clinical trials, the firm told us. Exosomes…